Rckt stock forecast moving average alignment supports a

Moving average alignment supports a bullish rckt stock forecast. Traders note the price lagging behind biotech sector leaders by 4%, suggesting room for catch-up rallies if broader industry strength continues. Despite these high-quality assets and revenue streams, RGNX trades as if its programs are deeply impaired. Even assigning only a 10% probability of success to the DMD program, a conservative sum-of-the-parts model yields a valuation far above current levels. RGNX represents a deeply undervalued platform with credible late-stage assets, strong partners, and meaningful near-term catalysts, mispriced due to FDA uncertainty rather than clinical fundamentals. We just received data on a new analyst forecast for $RCKT. Geulah Livshits from Chardan Capital set a price target of 11.0 for RCKT. Recent earnings guidance supports a mildly bullish rckt stock forecast. The company reported reduced burn rate and improved cash flow outlook, aligning with sector-wide strength as healthcare innovation stocks gain traction among long-term growth funds.